mesenchymal stem cells
Trials 142 · started per year
News releases announcing trial results or a regulatory action · 37
| Date | Issuer | Release |
|---|---|---|
| 2026-05-07 | BioRestorative Therapies | Results BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease biorestorative.com ↗
At 52 weeks, 52% of evaluable patients achieved at least 50% improvement in both the Visual Analog Scale (“VAS”) for pain and the Oswestry Disability Index (“ODI”) for function. |
| 2025-09-10 | Hope Biosciences Research Foundation | Regulatory Hope Bio’s stem cells zero in on Crohn’s Disease hope.bio ↗
The U.S. Food and Drug Administration (FDA) has authorized a Phase II clinical trial to evaluate whether the stem cells manufactured through Hope’s proprietary technology affect signs and symptoms of Crohn’s Disease in suffering people. |
| 2025-06-12 | Hope Biosciences Research Foundation | Regulatory Hope Bio hope.bio ↗
The U.S. Food and Drug Administration (FDA) has authorized an open label Phase Ib/IIa clinical trial to evaluate whether Hope Biosciences autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) reduce inflammation in the brain, improve brain activity, and/or slow progression of AD. |
| 2025-05-07 | NextCell Pharma Ab | Results Study published in Nature Medicine shows promising results in Alzheimer’s disease – supports the development of ProTrans at NextCell nextcellpharma.com ↗
The treatment led to improved cognitive symptoms, reduced neuroinflammation, and slower brain atrophy, with no reported serious adverse events. |
| 2025-02-04 | Cynata Therapeutics Limited | Results Publication comparing Cymerus MSCs to other MSCs cynata.com ↗
A paper comparing Cynata’s Cymerus™ iPSC1-derived MSC s2 and MSCs from various other sources has been published in npj Regenerative Medicine, a leading peer-reviewed journal published by Nature Portfolio. |
| 2024-11-01 | Hope Biosciences Research Foundation | Results Hope Biosciences Shares Promising Topline Results in Multiple Sclerosis hope.bio ↗ |
| 2023-12-18 | Personalized Stem Cells, Inc. | Results PSC Knee Osteoarthritis Stem Cell Research Results personalizedstemcells.com ↗
Personalized Stem Cells (PSC) has completed the first ever FDA-approved clinical trial of GMP lab manufactured ASCs for patients with knee osteoarthritis. |
| 2023-10-17 | Takeda | Results Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas takeda.com ↗
The safety profile for darvadstrocel was consistent with prior studies and there were no new safety signals identified. |
| 2023-09-13 | Hope Biosciences Research Foundation | Results The Leo Effect: Why Hope Bio hope.bio ↗
Owing to their immunomodulatory and regenerative capabilities, MSCs may constitute a promising approach to “failure to thrive” cases in a variety of disease conditions. |
| 2023-08-08 | NextCell Pharma Ab | Results ProTrans and NextCell gain international attention nextcellpharma.com ↗
Results from Professor Per-Ola Carlsson, Principal Investigator for NextCell’s Phase-I/II study with ProTrans stromal cells for Type 1 Diabetes are now published and featured in the Up-front section of the current issue of Diabetologia. |
| 2022-08-28 | Cynata Therapeutics Limited | Results Preclinical study in coronary artery disease published cynata.com ↗ |
| 2022-03-08 | Hope Biosciences Research Foundation | Results Hope Biosciences’ Cell Therapy Shown Safe, Beneficial for Rheumatoid Arthritis hope.bio ↗
Administration of HB-adMSCs resulted in a favorable safety profile, significant and persistent improvements in joint functions, and modest improvements in inflammatory marker C-reactive protein (CRP). |
| 2022-02-18 | Takeda | Results Alofisel ® ▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study 1,2 takeda.com ↗
Takeda ( TSE:4502/NYSE:TAK ) today announced the first six-month interim analysis results from INSPIRE, in which clinical remission * was observed in 65% of patients in both cohorts who were evaluated at 6 months. |
| 2021-09-27 | Takeda | Regulatory Takeda Receives Approval to Manufacture and Market Alofisel ® ▼ (darvadstrocel) in Japan for Treatment of Complex Perianal Fistulas in Patients with Non-active or Mildly Active Luminal Crohn’s Disease takeda.com ↗
Alofisel (darvadstrocel) is the first expanded human allogeneic adipose-derived mesenchymal stem cell therapy to be approved in Japan |
| 2021-09-27 | Cynata Therapeutics Limited | Results CYP Preclinical Heart Attack Study Published in Cytotherapy cynata.com ↗
The paper, entitled “ Pluripotent stem cell derived mesenchymal stromal cells improve cardiac function and vascularity after myocardial infarction”, has been published online on the Cytotherapy website, and will appear in a print edition in the near future. |
| 2020-12-08 | Citius Pharmaceuticals, Inc. | Results Citius Pharmaceuticals Subsidiary NoveCite Announces Data from a Study of Induced Mesenchymal Stem Cell ("i-MSC") Therapy in an in vivo Model of Acute Respiratory Distress Syndrome ("ARDS") citiuspharma.com ↗
The available results of i-MSC therapy in the study show improvement in critical parameters, such as improved oxygenation, less systemic shock, and reduced lung injury, compared to the control group. |
| 2020-09-27 | Stemedica Cell Technologies, Inc. | Regulatory FDA Grants IND Approval for Phase II Clinical Trial Using Stemedica’s itMSC Therapy for COVID-19 Patients stemedica.com ↗ |
| 2020-09-23 | Cynata Therapeutics Limited | Results Potential Utility of Cymerus MSCs in Heart Attack Model cynata.com ↗
In particular, treatment with Cymerus MSCs was shown to enhance the recovery of the blood supply to the damaged heart through the generation of new blood vessels. |
| 2020-09-14 | Cynata Therapeutics Limited | Results Cynata Clinical Trial Results Published in Nature Medicine cynata.com ↗
Overall Response rate by Day 100 was 87% (13/15 patients showed an improvement in GvHD severity by at least one grade compared to baseline) |
| 2020-08-17 | Stempeutics Research Pvt Ltd | Regulatory Alkem and Stempeutics collaborate for launch of Stempeucel®, first ‘Made in India’ Cell Therapy to treat Critical Limb Ischemia stempeutics.com ↗
Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel® in India. |
| 2020-07-28 | Stemedica Cell Technologies, Inc. | Results Stemedica in the News! ProMedica Researchers Observe Encouraging Outcomes with Use of Allogeneic Stem Cells in COVID-19 Patients stemedica.com ↗
ProMedica today announced the promising results of its new study that evaluated the use of stem cells in the treatment of adult COVID-19 patients. |
| 2020-04-21 | Hope Biosciences Research Foundation | Regulatory Hope Biosciences Announces Third FDA-approved Clinical Trial for COVID-19 hope.bio ↗
Hope Biosciences announces FDA approval on their third clinical trial for COVID-19. |
| 2020-04-20 | Stemedica Cell Technologies, Inc. | Regulatory FIRST COVID-19 PATIENT TREATED UNDER EMERGENCY USE IND AT PROVIDENCE SAINT JOHN’S HEALTH CENTER USING STEMEDICA ISCHEMIA-TOLERANT ALLOGENEIC MESENCHYMAL BONE MARROW CELLS stemedica.com ↗
A single patient, emergency Investigational New Drug (IND) use was cleared by the U.S. Food and Drug Administration |
| 2020-04-06 | Hope Biosciences Research Foundation | Regulatory Stem Cell FDA approved trial hope.bio ↗
FDA has approved a Phase II clinical trial evaluating efficacy and safety of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) to provide immune support against COVID-19. |
| 2019-11-20 | Hope Biosciences Research Foundation | Regulatory Hope Biosciences Receives FDA Approval to Commence Groundbreaking Clinical Trial for Alzheimer hope.bio ↗
today announced that FDA has approved a Phase I/II clinical trial evaluating safety and efficacy of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) for Alzheimer’s Disease, in partnership with Altoida, Inc., a predictive digital biomarker company. |
| 2019-10-30 | Stemedica Cell Technologies, Inc. | Results Stemedica Reports Positive Results from Phase IIa Clinical Trial Using IV Administration of Mesenchymal Stem Cells for Ischemic Stroke stemedica.com ↗
Intravenous transfusion of low oxygen mesenchymal bone marrow cells in patients with disabling chronic stroke was safe and significantly improved several behavioral measures. |
| 2019-09-30 | Stemedica Cell Technologies, Inc. | Results Positive Study Results of Phase IIa Clinical Trial Using Intravenous Administration of Mesenchymal Stem Cells for Ischemic Stroke Published in Peer-Reviewed Stroke Journal stemedica.com ↗
Study testing disclosed no safety concerns. |
| 2019-09-13 | Stemedica Cell Technologies, Inc. | Results Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke stemedica.com ↗
All behavioral end points showed significant gains over the 12-months of follow-up. |
| 2019-01-07 | Stemedica Cell Technologies, Inc. | Results Stemedica Cell Technologies Reports Positive Data in Phase I/IIa Study of Allogeneic Stem Cells for Ischemic Stroke stemedica.com ↗
The data demonstrated that itMSCs administered intravenously appeared to be safe and well tolerated. |
| 2018-07-30 | Cynata Therapeutics Limited | Results Cymerus MSCs improve cardiac recovery in preclinical study cynata.com ↗
Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to announce positive efficacy data from a study of its Cymerus mesenchymal stem cells (MSCs) in a preclinical heart attack model. |
| 2018-01-23 | Longeveron Inc. | Results Longeveron Shares Promising State of Regenerative Medicine Research with Experts at the FDA, NIH and Other Leading Organizations at National Conference longeveron.com ↗
A single injection of the allogeneic mesenchymal stem cells, in fact, was associated with significant gains in functional capacity in both Phase I and Phase II studies Longeveron published in The Journals of Gerontology in 2017. |
| 2017-10-23 | Longeveron Inc. | Results University Of Miami Miller School of Medicine: Stem Cell Studies Build Momentum toward Therapy for Age-Associated Frailty longeveron.com ↗
Now Phase II randomized, placebo-controlled trial findings have verified their initial study, boosting the potential for this stem cell therapy to reverse or forestall the symptoms of frailty. |
| 2017-02-17 | Takeda | Results Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn's Disease Patients with Cx601 takeda.com ↗
Of those mITT patients who had shown combined remission at week 24, a greater number in the Cx601 group versus the control group reported no relapse at week 52 (75.0% and 55.9%). |
| 2016-05-18 | Stemedica Cell Technologies, Inc. | Regulatory FDA Grants IND Approval To Stemedica For A Traumatic Brain Injury Phase IIa Clinical Trial stemedica.com ↗
Stemedica Cell Technologies, Inc. (Stemedica) received an FDA investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its ischemic tolerant, adult allogeneic mesenchymal stem-cells (itMSC) to treat subjects with traumatic brain injury (TBI). |
| 2016-01-27 | Cynata Therapeutics Limited | Regulatory CYP Receives Favourable Advice from UK Regulatory Authority cynata.com ↗
The MHRA confirmed that Cynata’s proprietary Cymerus™ mesenchymal stem cell (MSC) product, CYP-001, is considered to be suitable for use in a proposed Phase 1 clinical trial in patients with graft versus host disease. |
| 2016-01-11 | Cynata Therapeutics Limited | Results Cynata CLI Study Published in Peer Reviewed Journal cynata.com ↗
This marks the first published in vivo study of Cynata’s proprietary Cymerus MSCs and demonstrates the beneficial effect of MSCs manufactured using Cynata’s unique technology in treating CLI. |
| 2015-06-09 | Stemedica Cell Technologies, Inc. | Regulatory FDA Grants IND Approval for Phase IIa Clinical Trial Using Stemedica’s ITMSC Therapy to Treat Alzheimer’s Disease stemedica.com ↗
Stemedica Cell Technologies, Inc. received the FDA’s investigational new drug (IND) approval |
All press releases naming this drug 39 releases
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 173 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mesenchymal stem cells | “A multicenter phase I/II Clinical trial,randomized, controlled with placebo, triple blind to evaluate the safety of the intravenous administration of 3 doses of autologous...” NCT02290886 ↗153“Participants will be treated with mesenchymal stem cells (MSCs) eye drops, 5×10\^5 /50μl in each eye, twice a day for two weeks and they will be followed up for three months...” NCT05784519 ↗ “The purpose of this study is to assess the safety and efficacy of injectable collagen scaffold combined with Mesenchymal stem cells (MSCs) transplantation in patients with brain injury.” NCT02767817 ↗ “Mesenchymal stem cells originating from allogenic umbilical cord produced under GMP conditions will be administered in 3 times, with doses indicated below, intravenously within 1 week.” NCT04392778 ↗ “Mesenchymal stem cells (MSCs) play an important role in embryonic development and tissue regeneration in adult life owing to their high competency and self-renewal features.” PMID 25986622 ↗ 2015 “These treatments, utilizing mesenchymal stem cells (MSCs), aim to restore ocular surface health in conditions like DED by reducing inflammation and enhancing tissue repair.” NCT07191847 ↗ “Mesenchymal stem cells: intravenous infusion, 2×10⁶ cells/kg body weight/week (once weekly), with 1 to 4 administrations based on different dosage groups.” NCT07212335 ↗ “Transdermal injection of the filler agent composed of mesenchymal stem cells derived from autologous adipose tissue associated with hyaluronic acid.” NCT02034786 ↗ “Mesenchymal stem cells (MSC) are a form of multipotent adult stem cells that can be isolated from bone marrow (BM), adipose tissue, and cord blood.” NCT02083731 ↗ “Mesenchymal stem cells (MSCs) have shown immunomodulatory and regenerative effects in preclinical models and early clinical studies.” PMID 42081777 ↗ May 2026 “Mesenchymal stem cells (MSCs) exhibit immunomodulatory, tissue-protective, and repair-promoting properties in vitro and in animals.” PMID 28381130 ↗ Apr 2017 |
| Known as | ADMSCs | “Allogenic adipose derived MSCs (ADMSCs) which were obtained from a healthy donor were applied to all patients in the study group.” NCT05283317 ↗ |
| Known as | AlloJoin | “A Multicenter, Randomized, Double-blind, Controlled Phase III Trial of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells (AlloJoin®) Therapy for Knee Osteoarthritis.” NCT06570291 ↗ |
| Known as | ASCs | “using expanded autologous adipose-derived stem cells (ASCs) in cellular therapy for the treatment of PAD patients who developed chronic artery ulcers.” PMID 40202953 ↗ Apr 2025 |
| Known as | BM-MSC | “A single dose of autologous BM-MSC will be injected intravenously.” NCT02035514 ↗ |
| Known as | BM-MSCs | “We hypothesize that bone marrow mesenchymal stromal cells (BMMSCs) are renotropic and may improve kidney function via anti-apoptotic, anti-fibrotic, and anti-inflammatory effects.” PMID 28535817 ↗ May 20171“following intravenous injection of autologous bone marrow-derived MSCs (BM-MSCs).” PMID 37496411 ↗ Apr 2023 |
| Known as | Bone Marrow Mesenchymal Stem Cells | “A Open Labeled and Self Controlled, Safety/Efficacy Assessed Pilot Study on Transplantation Therapy Using Bone Marrow Mesenchymal Stem Cells for Insulin Resistance of Type 2...” NCT01142050 ↗ |
| Known as | bone marrow mesenchymal stromal cells | “We hypothesize that bone marrow mesenchymal stromal cells (BMMSCs) are renotropic and may improve kidney function via anti-apoptotic, anti-fibrotic, and anti-inflammatory effects.” PMID 28535817 ↗ May 2017 |
| Known as | bone-marrow-derived-MSCs | “receive IV 1-2×10(6) bone-marrow-derived-MSCs/Kg or placebo” PMID 25436769 ↗ Dec 2014 |
| Known as | CELULAS TRONCO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06326203 ↗ |
| Known as | Chondrogen | “Chondrogen is a preparation of adult mesenchymal stem cells (MSCs) in a solution containing hyaluronic acid.” NCT00225095 ↗ |
| Known as | CSM | “Implantation of autologous mesenchymal stem cells (CSM) expanded "in vitro" and administered directly into the lung suture line” NCT02045745 ↗ |
| Known as | hMSCs | “A single dose, one time infusion (in the vein) of one of the following doses of human mesenchymal stem cells (hMSCs): 1 x 10\^6, 3 x 10\^6 or 5 x 10\^6 human mesenchymal stem...” NCT02866721 ↗ |
| Known as | IT-MSC | “This is a single-institution dose escalation study to determine the maximum tolerated dose (MTD) of intrathecally administered allogeneic, 3rd party mesenchymal stem cells...” NCT02410239 ↗ |
| Known as | IV-MSC | “Mesenchymal stem cells (IV-MSC)” NCT06030648 ↗ |
| Known as | mesenchymal stromal cells | “intrathecal and intravenous administration of autologous mesenchymal stem cells (MSCs) (also called mesenchymal stromal cells) in patients with multiple sclerosis (MS) and...” PMID 20937945 ↗ Oct 20103“autologous bone marrow-derived mesenchymal stromal cells (MSCs) as part of a phase 1 study focused on the safety and feasibility of this cell therapy.” PMID 29963053 ↗ Jun 2018 “A Phase I Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Xerostomia After Radiation Therapy for Head and Neck Cancer” NCT05820711 ↗ “10⁶ mesenchymal stromal cells/mesenchymal stem cells (MSCs) derived from dental pulp” NCT07305623 ↗ |
| Known as | mesenchymal stromal/stem cells | “Mesenchymal stromal/stem cells (MSCs) are cells that can be derived from umbilical cords, bone marrow, adipose tissue, and dental pulp, among other sites.” NCT03171194 ↗ |
| Known as | MKH | “Mesenchymal stem cells (MKH) not only inhibit the abnormal activation of T lymphocytes and macrophages, but also encourage them to differentiate into regulatory T cell subsets...” NCT04392778 ↗ |
| Known as | MSC | “The principal aim of this trial is to assess the safety of non-mutated HLA-identical Mesenchymal stem cell (MSC) transplantation for OI pediatric patients irrespective of...” NCT02172885 ↗22“Mesenchymal stem cells (MSC) are a form of multipotent adult stem cells that can be isolated from bone marrow (BM), adipose tissue, and cord blood.” NCT02083731 ↗ “Third party donor Mesenchymal Stem Cells (MSC) will be administered via intrathecal administration at the assigned dose on days 0, 7 and 14.” NCT02410239 ↗ “Umbilical cord-derived mesenchymal stem cells (MSCs), produced by Yeditepe University, at a concentration of 10 million MSCs per 1 mL.” NCT07838454 ↗ “Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration in animal models of MS” PMID 31072380 ↗ May 2019 “Mesenchymal stem cell (MSC) infusion could represent a novel tolerogenic cell therapy in kidney transplantation.” NCT00752479 ↗ “A Pilot Safety Study of the Administration of Mesenchymal Stem Cells (MSC) in the Treatment of Burn Wounds” NCT02104713 ↗ “Augmentation of atrophied alveolar ridge with mesenchymal stem cells( MSC) and bis calcium phosphate(BCP)” NCT02751125 ↗ “Mesenchymal stem cells (MSC) have been demonstrated to decrease immune responses of the host” NCT01213186 ↗ “The plasticity of Mesenchymal Stem Cells (MSC) regulates inflammation and immunity.” NCT04416139 ↗ “Mesenchymal stem cells (MSC) have been shown to have immunosuppressive properties.” NCT00314483 ↗ |
| Known as | MSCs | “Mesenchymal stem cells (MKH) not only inhibit the abnormal activation of T lymphocytes and macrophages, but also encourage them to differentiate into regulatory T cell subsets...” NCT04392778 ↗54“This Phase IIB, multicenter, double-blind, randomized, and uncontrolled clinical trial aims to assess the efficacy and safety of subconjunctival injection of Mesenchymal Stem...” NCT06905834 ↗ “Purpose: This prospective clinical case series aimed to evaluate the effect of suprachoroidal implantation of mesenchymal stem cells (MSCs) in the form of spheroids as a stem...” NCT05712148 ↗ “Among several treatment modalities, mesenchymal stem cells (MSCs) transplantation is promising for autoimmune disorders due to immunomodulation, regeneration, and migration to...” PMID 35725652 ↗ Jun 2022 “intrathecal and intravenous administration of autologous mesenchymal stem cells (MSCs) (also called mesenchymal stromal cells) in patients with multiple sclerosis (MS) and...” PMID 20937945 ↗ Oct 2010 “A single patient safety study for harvesting, expanding ex vivo and injecting autologous mesenchymal stem cells (MSC's) into the subarachnoid space of a patient with...” NCT01142856 ↗ “Mesenchymal stem cells (MSCs) are particularly attractive therapeutic agents because of their ability to self-renew, differentiate into multi lineage cell types, and locally...” NCT02387749 ↗ “This study was designed to provide confirmation of safety of mesenchymal stem cells (MSCs) therapy in chronic renal failure due to autosomal dominant polycystic kidney disease (ADPKD).” NCT02166489 ↗ “The therapeutic and immunomodulatory potential of mesenchymal stem cells (MSCs) in rheumatoid arthritis (RA) has attracted considerable scientific attention in recent decades.” PMID 37496411 ↗ Apr 2023 “Mesenchymal stem cells (MSCs) play an important role in embryonic development and tissue regeneration in adult life owing to their high competency and self-renewal features.” PMID 25986622 ↗ 2015 “The therapeutic plasticity of mesenchymal stem cells (MSCs) may be an attractive therapy to this complex disease, turning MSCs strong candidates for cellular therapy in ALS.” NCT02987413 ↗ |
| Known as | Stem Cells,Mesenchymal | “Biological: Stem Cells,Mesenchymal” NCT02334878 ↗ |
| Known as | UC-MSCs | “Umbilical cord derived mesenchymal stem cells (UC-MSCs) derived from mesoderm” NCT03550183 ↗ |
| Known as | Umbilical Cord Derived Mesenchymal Stem Cells | “Umbilical Cord Derived Mesenchymal Stem Cells at a dose of 100-800 million by intravenous infusion” NCT01962233 ↗ |
| Action | Restore | “make its differentiation to form new blood capillary, improve and restore the local blood flow.” NCT02304588 ↗ |
| Modality | Cell therapy | “allogeneic human mesenchymal stem cells” PMID 24430407 ↗ Jan 2014 |
| Route | Other | “intra-articular injection of human mesenchymal stem cells into the knee” PMID 24430407 ↗ Jan 2014 |